MX2016002720A - Metodo para mejorar la estabilidad del anticuerpo. - Google Patents

Metodo para mejorar la estabilidad del anticuerpo.

Info

Publication number
MX2016002720A
MX2016002720A MX2016002720A MX2016002720A MX2016002720A MX 2016002720 A MX2016002720 A MX 2016002720A MX 2016002720 A MX2016002720 A MX 2016002720A MX 2016002720 A MX2016002720 A MX 2016002720A MX 2016002720 A MX2016002720 A MX 2016002720A
Authority
MX
Mexico
Prior art keywords
asp
antibody
asn
residue
atom
Prior art date
Application number
MX2016002720A
Other languages
English (en)
Inventor
Hubert Kettenberger
Stefan Klostermann
Florian Lipsmeier
Apollon Papadimitriou
Jasmin Sydow-Andersen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016002720A publication Critical patent/MX2016002720A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Computing Systems (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con un método para seleccionar o deseleccionar un anticuerpo que comprende: a) determinar para cada residuo de Asp y Asn en una región de anticuerpo Fv, la flexibilidad conformacional del átomo Ca usando un montaje de modelo de homología, b) determinar para cada residuo de Asp y Asn en una región de anticuerpo Fv, el tamaño del residuo de aminoácido C-terminal al residuo de Asp o Asn, y c) seleccionar un anticuerpo en el que el átomo Ca es conformacionalmente inflexible y/o el residuo de Asp o Asn tiene un residuo de aminoácido C-terminal grande, o deseleccionar un anticuerpo en el que el átomo Ca tiene una flexibilidad conformacional moderada a alta y/o el Asp y Asn tiene un residuo de aminoácido C-terminal pequeño.
MX2016002720A 2013-09-06 2014-09-03 Metodo para mejorar la estabilidad del anticuerpo. MX2016002720A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13183389 2013-09-06
EP13184174 2013-09-12
PCT/EP2014/068649 WO2015032776A1 (en) 2013-09-06 2014-09-03 Method for improving antibody stability

Publications (1)

Publication Number Publication Date
MX2016002720A true MX2016002720A (es) 2016-06-08

Family

ID=51485608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002720A MX2016002720A (es) 2013-09-06 2014-09-03 Metodo para mejorar la estabilidad del anticuerpo.

Country Status (11)

Country Link
US (2) US10418126B2 (es)
EP (2) EP3761033A3 (es)
JP (1) JP6580570B2 (es)
KR (1) KR20160052562A (es)
CN (1) CN105518461B (es)
CA (1) CA2918191A1 (es)
DK (1) DK3042205T3 (es)
HK (1) HK1223684A1 (es)
MX (1) MX2016002720A (es)
RU (1) RU2711719C2 (es)
WO (1) WO2015032776A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093978B2 (en) 2013-08-12 2018-10-09 Genentech, Inc. Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
CR20160561A (es) * 2014-05-01 2017-05-03 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
CN114207728A (zh) * 2019-08-02 2022-03-18 杰南技术公司 通过基于物理的模拟预测聚合物中的侧链降解

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100736A (en) * 1870-03-15 dundeedale
RU2134724C1 (ru) * 1992-08-24 1999-08-20 Ниссин Сокухин Кабусики Кайся Гуманизированное антитело и способ его получения, полинуклеотид (варианты), гибридомная клеточная линия (варианты)
AU2005287557B2 (en) * 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
JP5374359B2 (ja) * 2006-03-17 2013-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定化されたポリペプチド化合物
EP3202786A3 (en) * 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
JP5745720B2 (ja) * 2008-06-25 2015-07-08 エスバテック − ア ノバルティスカンパニー エルエルシー イムノバインダーの溶解性の最適化
JP5990102B2 (ja) * 2009-09-29 2016-09-07 ユニフェルシテイト ヘント ホスホ−６−マンノースへのマンノース−１−ホスホ−６−マンノース結合の加水分解
WO2015140126A1 (en) * 2014-03-21 2015-09-24 F. Hoffmann-La Roche Ag In vitro prediction of in vivo half-life of antibodies
WO2015144932A1 (en) * 2014-03-28 2015-10-01 Novozymes A/S Enzyme variants and polynucleotides encoding same
BR112016027884B1 (pt) * 2014-05-30 2023-05-02 Novozymes A/S Variante de uma xilanase da família 11 de gh genitora, polinucleotídeo, construção de ácido nucleico, vetor de expressão, célula hospedeira, e, métodos de produção de uma variante de xilanase da família 11 de gh e de degradação de um material contendo xilana

Also Published As

Publication number Publication date
US20200066372A1 (en) 2020-02-27
EP3761033A3 (en) 2021-01-20
RU2711719C2 (ru) 2020-01-21
US20160275238A1 (en) 2016-09-22
KR20160052562A (ko) 2016-05-12
EP3042205A1 (en) 2016-07-13
CN105518461A (zh) 2016-04-20
CN105518461B (zh) 2018-04-13
RU2016111352A3 (es) 2018-05-23
EP3042205B1 (en) 2019-12-25
WO2015032776A1 (en) 2015-03-12
JP6580570B2 (ja) 2019-09-25
DK3042205T3 (da) 2020-03-02
US10418126B2 (en) 2019-09-17
RU2016111352A (ru) 2017-10-11
EP3761033A2 (en) 2021-01-06
CA2918191A1 (en) 2015-03-12
HK1223684A1 (zh) 2017-08-04
JP2016530288A (ja) 2016-09-29

Similar Documents

Publication Publication Date Title
PH12018501839A1 (en) St2l antagonists and methods of use
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
PH12014501758B1 (en) Cd47 antibodies and methods of use thereof
EA201690280A1 (ru) Композиции и способы, относящиеся к выделенным эндофитам
TN2014000438A1 (en) Anti-fcrn antibodies
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX2013009679A (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
MX363193B (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2016002720A (es) Metodo para mejorar la estabilidad del anticuerpo.
PH12016500753B1 (en) Antibodies specific to fcrn
NZ717399A (en) Antibodies against csf-1r
IL246202A0 (en) Methods for t-cell epitope sorting, preparation of t-cell preparations and treatment of diseases
AU2012285875A8 (en) Use of c-Fms antagonists
MX2021010472A (es) Anticuerpos neutralizantes de gm-csf para usarse en el tratamiento de artritis reumatoide o como analgesicos.
UA117466C2 (uk) СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
ZA201603098B (en) Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
MX2015015023A (es) Metodo para la determinacion de cobre libre.
UY34564A (es) Utilización en terapéutica de derivados de imidazopiridina